Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Leukemia ; 32(3): 685-693, 2018 03.
Article in English | MEDLINE | ID: mdl-28824170

ABSTRACT

Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and 13 t(14;18)-negative FL were analyzed, followed by the integration of copy-number changes, copy-neutral LOH and published gene-expression data as well as the assessment of immunoglobulin N-glycosylation sites. Typical FL mutations also affected t(14;18)-negative FL. Curated gene set/pathway annotation of genes mutated in either t(14;18)-positive or t(14;18)-negative FL revealed a strong enrichment of same or similar gene sets but also a more prominent or exclusive enrichment of immune response and N-glycosylation signatures in t(14;18)-negative FL. Mutated genes showed high BCL2 association in both subgroups. Among the genes mutated in t(14;18)-negative FL 555 were affected by copy-number alterations and/or copy-neutral LOH and 96 were differently expressed between t(14;18)-positive and t(14;18)-negative FL (P<0.01). N-glycosylation sites were detected considerably less frequently in t(14;18)-negative FL. These results suggest a diverse portfolio of genetic alterations that may induce or regulate BCL2 expression or promote pathogenesis of t(14;18)-negative FL as well as a less specific but increased crosstalk with the microenvironment that may compensate for the lack of N-glycosylation.


Subject(s)
Biomarkers, Tumor , Lymphoma, Follicular/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 18 , Computational Biology/methods , DNA Copy Number Variations , Glycosylation , Humans , Immunoglobulin Variable Region/genetics , Lymphoma, Follicular/metabolism , Mutation , Polymorphism, Single Nucleotide , Proto-Oncogene Proteins c-bcl-2/metabolism , Translocation, Genetic , Exome Sequencing
3.
Leukemia ; 31(6): 1363-1367, 2017 06.
Article in English | MEDLINE | ID: mdl-28017969

ABSTRACT

Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma. Lenalidomide binding to the Cereblon (CRBN) E3 ubiquitin ligase results in targeted ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) leading to growth inhibition of multiple myeloma cells. Recently, Basigin (BSG) was identified as another protein regulated by CRBN that is involved in the activity of lenalidomide. Here, we analyzed the prognostic value of IKZF1, IKZF3, CRBN and BSG mRNA expression levels in pretreatment plasma cells from 60 patients with newly diagnosed multiple myeloma uniformly treated with lenalidomide in combination with intensive chemotherapy within a clinical trial. We found that IKZF1 mRNA expression levels are significantly associated with progression-free survival (PFS). Patients in the lowest quartile (Q1) of IKZF1 expression had a superior PFS compared with patients in the remaining quartiles (Q2-Q4; 3-year PFS of 86 vs 51%, P=0.01). This translated into a significant better overall survival (100 vs 74%, P=0.03). Subgroup analysis revealed a significant impact of IKZF1, IKZF3 and BSG expression levels on PFS in cytogenetically defined standard-risk but not high-risk patients. Our data suggest a prognostic role of IKZF1, IKZF3 and BSG expression levels in lenalidomide-treated multiple myeloma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/genetics , Ikaros Transcription Factor/genetics , Multiple Myeloma/pathology , Adult , Aged , Dexamethasone/administration & dosage , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Lenalidomide , Male , Middle Aged , Multiple Myeloma/drug therapy , Multiple Myeloma/genetics , Neoplasm Staging , Prognosis , Survival Rate , Thalidomide/administration & dosage , Thalidomide/analogs & derivatives
6.
Arch Pharm (Weinheim) ; 333(2-3): 58-62, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10783519

ABSTRACT

In this study novel substituted 6-benzyl-thieno[2,3-b][1,4]thiazines with an urea moiety were synthesized. Structural modifications of the amino side chain were carried out with the aim of finding tissue specific compounds. The effects on papillary muscles, right atria, aortic strips, and terminal ilea were investigated. Compounds 10c and 10d showed the most potent negative inotropic effect. The calcium antagonism of all derivatives occurred in a non-competitive manner, which may indicate that they also have potassium channel opening activities.


Subject(s)
Calcium Channel Blockers/chemical synthesis , Potassium Channels/drug effects , Thiazines/chemical synthesis , Thiazines/pharmacology , Animals , Aorta/drug effects , Calcium Channel Blockers/chemistry , Calcium Channel Blockers/pharmacology , Guinea Pigs , Heart Atria/drug effects , Ileum/drug effects , In Vitro Techniques , Magnetic Resonance Spectroscopy , Papillary Muscles/drug effects , Thiazines/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...